Pharma Impressed With Cell-Based RNAi Screens, But Acknowledges Limits | GenomeWeb
This article has been updated from a previous version, which mistakenly reported that Klaus Melchers presented information on Altana's research instead of Michael Byrne.
 
NEW YORK (GenomeWeb News) — Pharmaceutical firms think cell-based RNAi screens are valuable drug-discovery tools, but are finding that the approach still has a number of limitations, according to speakers at Cambridge Healthtech Institute’s Molecular Medicine Tri-Conference, held in San Francisco last week.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.